Bevacizumab is a humanized monoclonal antibody targeting VEGF that specifically binds to VEGF, blocks VEGR binding to VEGFR, and inhibits the angiogenic signaling pathway. Bevacizumab has antitumor activity and can inhibit tumor cell growth.

方法：人肺癌细胞 A549 用 Bevacizumab (1-25 µM) 处理 12-72 h，使用 CCK-8 assay 检测细胞增殖。
结果：Bevacizumab 治疗 A549 细胞 12 h，显示出对细胞增殖的轻度抑制，但 24 h 后显示出以剂量依赖性方式显著诱导细胞凋亡。[1]
方法：人肿瘤细胞 AGS、Caco2 和 HepG2/C3A 用 Bevacizumab (5 ng/mL-100 µg/mL) 处理 48 h，使用半定量 RT-PCR 检测端粒酶表达和活性。
结果：Bevacizumab (5 ng/mL) 使 AGS 中的 hTERT mRNA 水平增加 35.2%，Caco2 增加 62.0%，HepG2/C3A 增加 21.8%。而 Bevacizumab (100 µg/mL) 使 AGS 中的 hTERT mRNA 水平增加 42.3%，Caco2 增加 94.1%，HepG2/C3A 增加 52.5%。因此，Bevacizumab 显著增加了AGS、Caco2 和 HepG2/C3A 中的 hTERT mRNA 水平和端粒酶活性。[2]

方法：为研究抗肿瘤活性，将 Bevacizumab (2-5 mg/kg) 腹腔注射给携带人骨肉瘤细胞 143B-RFP 异种移植物的裸鼠，每周两次，持续 43 天。
结果：Bevacizumab 在裸鼠模型的实验性骨肉瘤中表现出强大的抗血管生成活性，但不影响肺转移的发生率。[3]

The binding kinetics of Bevacizumab or FD006 to VEGF is measured using Bio-Layer Inter-Ferometry on Octet RED. The assay is conducted at 30°C in PBS buffer. Sensor tips are pre-wet for 15 mins in buffer immediately prior to use, and the microplates are filled with 200 μL per well of diluted samples (VEGF) or buffer and agitated at 1000 rpm. The anti-human IgG biosensor are pre-saturated with Bevacizumab or FD006 (10 μg/mL) and washed in buffer for 120 seconds, and then transferred to VEGF at concentrations of 10 μg/mL, 3 μg/mL and 1 μg/mL. The VEGF association and dissociation rates are measured for 5mins and 10mins, respectively. The Kinetics parameters (Kon and Koff) and affinities (KD) are calculated from a non-linear global fit using the Octet analysis software. Multiple independent measurements are performed[2].

Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium supplemented with 5% heat-inactivated FCS, 100 U/mL Penicillin, 100 U/mL Streptomycin, and endothelial cell growth supplement. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].